financetom
Business
financetom
/
Business
/
Jio BlackRock gets regulatory approval to operate as investment adviser in India
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Jio BlackRock gets regulatory approval to operate as investment adviser in India
Jun 11, 2025 3:55 AM

(Reuters) -Jio BlackRock Investment Advisers (JBIAPL) has received approval from India's markets regulator to operate as an investment adviser, according to its parent company, Jio Financial Services .

JBIAPL is a 50:50 joint venture of the billionaire Mukesh Ambani-led Reliance Industries with Blackrock ( BLK ), the world's largest asset manager.

Earlier this year, both entities invested 665 million rupees ($7.78 million) into the joint venture, bringing their total investment to 845 million rupees.

The approval adds to Jio-BlackRock's growing financial services footprint in India.

Jio BlackRock has also recently received approval from the Securities and Exchange Board of India to launch its mutual fund business in the country.

Jio Financial Services' shares closed 0.05% lower on Wednesday.

($1 = 85.5020 Indian rupees)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
United Parcel Service Unusual Options Activity For December 09
United Parcel Service Unusual Options Activity For December 09
Dec 9, 2024
Investors with a lot of money to spend have taken a bullish stance on United Parcel Service ( UPS ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something...
Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform
Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform
Dec 9, 2024
01:40 PM EST, 12/09/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) said Monday it is presenting new data analysis of potential allogeneic cell therapy P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma as well as new preclinical data supporting P-CD19CD20-ALLO1's anti-cancer profile. Interim clinical data from its phase 1 trial of P-BCMA-ALLO1 showed a 91% overall response rate in the...
Newmont lays off nearly a dozen managers in restructuring move, Bloomberg News reports
Newmont lays off nearly a dozen managers in restructuring move, Bloomberg News reports
Dec 9, 2024
Dec 9 (Reuters) - Gold miner Newmont ( NEM ) let go of nearly a dozen managers, including a member of its executive team, as part of a corporate overhaul, Bloomberg News reported on Monday, citing people familiar with the matter. ...
Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data from Cancer Drug Study
Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data from Cancer Drug Study
Dec 9, 2024
01:32 PM EST, 12/09/2024 (MT Newswires) -- Rigel Pharmaceuticals ( RIGL ) said Monday R289 showed promising initial efficacy and safety data in its ongoing phase 1b study evaluating safety and tolerability in patients with relapsed or refractory lower-risk myelodysplastic syndrome. The drug candidate has demonstrated evidence of transfusion independence in elderly patients, Chief Medical Officer Lisa Rojkjaer said. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved